BioFuel Energy Corp. (NASDAQ:BIOF), is now caught in unexpected queries on pollution caused by corn emissions. The query thus far has been on leftovers of corn – which are also called as corn stover- causing as much gasoline emissions as carbon. BioFuel Energy Corp. (NASDAQ:BIOF), shares after opening at $8.77 moved to $8.92 on last trade day and at the end of the day closed at $7.41. Company price to sales ratio in past twelve months was calculated as 0.12 and price to cash ratio as 2.33. BioFuel Energy Corp. (NASDAQ:BIOF), showed a negative weekly performance of 2.76%.
On April 29, 2014, ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), provided an update on both of its ongoing open-label Phase 2 clinical studies of ISIS-SMNRx in infants and children with spinal muscular atrophy (SMA) at the 66th American Academy of Neurology (AAN) meeting in Philadelphia, PA. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), shares down 6.85% in last trading session and ended the day on $29.39. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), return on equity ratio is recorded as -18.10% and its return on assets is -8.10%. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), yearly performance is 29.99%.
FuelCell Energy Inc (NASDAQ:FCEL)’s shares jumped 0.85% to $2.36. The compny is providing a power plant for a C$7.5 million ($6.7 million) project to convert landfill gas into electricity and carbon dioxide that nourishes plants at a greenhouse facility in British Columbia. FuelCell Energy Inc (NASDAQ:FCEL), shares moved down 5.22% in last trading session and was closed at $2.18, while trading in range of $ 2.04 – 2.22. FuelCell Energy Inc (NASDAQ:FCEL), year to date (YTD) performance is 54.61%.
Prothena Corporation PLC (NASDAQ:PRTA), surged 9.51% after the company announced that an abstract was published by the XIV International Symposium on Amyloidosis (ISA) and described interim data from an ongoing Phase 1 study of NEOD001, a monoclonal antibody in clinical development for the treatment of patients with AL amyloidosis and persistent organ dysfunction, as of the abstract submission date. Updated data will be presented for the first time at ISA in Indianapolis, Indiana. Prothena Corporation PLC (NASDAQ:PRTA), weekly performance is -22.58%. On last trading day company shares ended up $26.12. Prothena Corporation PLC (NASDAQ:PRTA), distance from 50-day simple moving average (SMA50) is -26.02%.